Havrix Monodose

Havrix Monodose is a hepatitis A vaccine containing inactivated hepatitis A virus (1440 ELU/0.5 mL) and algeldrate, supplied as a prefilled syringe for intramuscular or subcutaneous injection. Marketed in the EU, it stimulates active immunity against hepatitis A. The formulation allows a dose without reconstitution, suitable for travel use. It is intended for individuals who need hepatitis A prophylaxis before travel, during outbreaks, or as part of childhood immunization.

Havrix Monodose is indicated for the prevention of hepatitis A infection in various populations.

- Pre‑exposure prophylaxis for travelers to endemic areas. - Routine immunization of children as part of national vaccination programs. - Protection of individuals at occupational risk, such as laboratory workers. - Outbreak control in communities with ongoing hepatitis A transmission. - Post‑exposure prophylaxis for persons who have not previously been vaccinated, when administered promptly. - Immunization of people with chronic liver disease who are at higher risk of severe hepatitis A.

Adverse reactions reported after Havrix Monodose are generally mild and transient.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or malaise. - Nausea. - Mild muscle aches.

Serious: - Severe allergic reaction (anaphylaxis). - Guillain‑Barré syndrome (rare). - Thrombocytopenia. - High‑grade fever persisting more than 48 hours. - Neurologic symptoms such as weakness or paresthesia. - Seizures (very rare).

Before administering Havrix Monodose, healthcare providers should consider several precautionary measures.

- Confirm no severe allergy to any vaccine component, especially gelatin or yeast proteins. - Defer vaccination in individuals with acute moderate or severe illness until recovery. - Use caution in persons with weakened immune systems; vaccine may be less effective. - Pregnancy status should be assessed; vaccine is generally avoided unless benefits outweigh potential risks. - Evaluate for history of thrombocytopenia or bleeding disorders before intramuscular injection. - Ensure proper storage and handling to maintain vaccine potency.

Havrix Monodose has limited known drug interactions, but certain situations warrant attention.

Avoid: - Concomitant administration of live viral vaccines (e.g., measles‑mumps‑rubella) within 4 weeks, as immune response may be reduced.

Use with caution: - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish antibody response. - Antipyretics (acetaminophen, ibuprofen) taken prophylactically may mask fever, though they do not affect immunogenicity. - Blood products given within 2 weeks may interfere with vaccine efficacy. - Chronic liver disease medications may require timing adjustments.